Innate Pharma Shares Fall Premarket on FDA Partial Study Hold
By Colin Kellaher
Shares of Innate Pharma dropped in premarket trading Thursday after the biopharmaceutical company said the U.S. Food and Drug Administration placed a partial hold on studies of its lead proprietary program lacutamab following the death of a patient.
Innate said the partial hold, which pauses new patient enrollment in its ongoing Phase 2 and Phase 1b studies of lacutamab, follows a fatal case of hemophagocytic lymphohistiocytosis, a rare hematologic disorder.
The Marseille, France, company said it is working to address requests from the FDA, including the incorporation of risk mitigation and management strategies for hemophagocytic lymphohistiocytosis in the lacutamab studies.
Innate noted that patients already on study treatment who are deriving clinical benefit can continue treatment, and that it doesn't expect any delay in the Phase 2 study data, as all patients had already been recruited.
Innate shares, which closed Wednesday at $2.47, were recently down 11% to $2.19 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 05, 2023 07:59 ET (11:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
The 10 Best Companies to Invest in Now
-
New 4-Star Stocks
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth